Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED BALANCE SHEETS

v2.4.0.8
CONSOLIDATED BALANCE SHEETS (USD $)
Dec. 31, 2013
Dec. 31, 2012
Current assets    
Cash    $ 782
Total current assets    782
Fixed assets - net 1,230 1,496
Total Assets 1,230 2,278
Current liabilities    
Accounts payable 421,597 298,994
Accrued interest payable 268,950 159,355
Notes payable - current - related parties 573,516 390,915
Notes payable - current, net 612,342 187,064
Derivative liability 150,067 463,037
Stock subscription payable - current 26,000 26,000
Related party payables 190,765 351,310
Other payables 238,085 158,006
Total current liabilities 2,481,322 2,034,681
Notes payable - related parties 167,007 363,888
Total Liabilities 2,648,329 2,398,569
Stockholders' Deficit    
Common stock, $.00001 par value; 100,000,000 shares authorized; 34,146,712 and 30,315,554 shares issued and outstanding as of December 31. 2013 and 2012, respectively 342 303
Additional paid in capital 12,415,639 11,903,279
Accumulated deficit (15,032,660) (14,274,244)
Total Transbiotec, Inc. stockholders' deficit (2,616,679) (2,370,662)
Noncontrolling interest (30,420) (25,629)
Total Stockholders' Deficit (2,647,099) (2,396,291)
Total Liabilities and Stockholders' Deficit $ 1,230 $ 2,278